PMID- 31187530
OWN - NLM
STAT- MEDLINE
DCOM- 20190620
LR  - 20190620
IS  - 1099-1069 (Electronic)
IS  - 0278-0232 (Linking)
VI  - 37 Suppl 1
DP  - 2019 Jun
TI  - Rare mature B-cell lymphomas in children and adolescents.
PG  - 53-61
LID - 10.1002/hon.2585 [doi]
AB  - Pediatric-type follicular lymphoma (PTFL), pediatric nodal marginal zone lymphoma 
      (pnMZL), and large B-cell lymphoma (LBCL) with IRF4 rearrangement have been 
      introduced into the current World Health Organization (WHO) classification. They 
      account for 5% to 10% of mature B-cell lymphomas in children and adolescents. 
      Both PTFL and pnMZL predominantly affect male adolescents and usually present 
      with localized lymphadenopathy in the head and neck region. The cells within the 
      follicles of PTFL typically show high-grade cytology, IGH monoclonality and lack 
      the t(14;18) chromosomal alteration. In contrast, pnMZL is characterized by 
      progressive transformation of germinal center (PTGC)-like features and 
      interfollicular proliferation of the cells with expansion of the marginal zones 
      with diffuse areas. Watch and wait after complete resection seems an adequate 
      therapy with chemotherapy restricted to incompletely resected disease. All 
      children with PTFL and pnMZL reported, so far, survived. B-cell lymphomas 
      presenting in the Waldeyer's ring are characterized by the expression of 
      IRF4/MUM1 and often associated with IRF4 rearrangements. Because of the frequent 
      diffuse component, treatment often follows current protocols for mature B-NHL. 
      The prognosis is excellent.
CI  - (c) 2019 John Wiley & Sons, Ltd.
FAU - Woessmann, Wilhelm
AU  - Woessmann W
AD  - Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, 
      Hamburg, Germany.
FAU - Quintanilla-Martinez, Leticia
AU  - Quintanilla-Martinez L
AD  - Institute of Pathology and Neuropathology, Eberhard Karls University of Tubingen 
      and Comprehensive Cancer Center, Tubingen University Hospital, Tubingen, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Hematol Oncol
JT  - Hematological oncology
JID - 8307268
RN  - 0 (Interferon Regulatory Factors)
RN  - 0 (interferon regulatory factor-4)
SB  - IM
MH  - Adolescent
MH  - Age Factors
MH  - Biopsy
MH  - Child
MH  - Combined Modality Therapy
MH  - Humans
MH  - Immunohistochemistry
MH  - Interferon Regulatory Factors/genetics/metabolism
MH  - Lymphoma, B-Cell/*diagnosis/epidemiology/etiology/therapy
MH  - Lymphoma, B-Cell, Marginal Zone/diagnosis/epidemiology/therapy
MH  - Lymphoma, Follicular/diagnosis/epidemiology/therapy
MH  - Molecular Diagnostic Techniques
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Treatment Outcome
EDAT- 2019/06/13 06:00
MHDA- 2019/06/21 06:00
CRDT- 2019/06/13 06:00
PHST- 2019/06/13 06:00 [entrez]
PHST- 2019/06/13 06:00 [pubmed]
PHST- 2019/06/21 06:00 [medline]
AID - 10.1002/hon.2585 [doi]
PST - ppublish
SO  - Hematol Oncol. 2019 Jun;37 Suppl 1:53-61. doi: 10.1002/hon.2585.